Sindrome.del.Ovario.Poliquistico

Tratamiento en mujeres sin deseo genésico 113
the efficacy of spironolactone versus
flutamide in the treatment of hirsutism.
Fertil Steril. 1994;61(4):613-6.
50
Venturoli S, Paradisi R, Bagnoli A,
Colombo FM, Ravaioli B, Vianello F, et
al. Low-dose flutamide (125 mg/day) as
maintenance therapy in the treatment
of hirsutism. Horm Res. 2001;56:25-31.
51
Muderris II, Bayram F. Clinical efficacy
of lower dose flutamide 125 mg/day in
the treatment of hirsutism. J Endocrinol
Invest. 1999; 22:165-8.
52
Dodin S, Faure N, Cedrin I, Mechain
C, Turcot-Lemay L, Guy J, et al. Clinical
efficacy and safety of low-dose
flutamide alone and combined with an
oral contraceptive for the treatment of
idiopathic hirsutism. Clin Endocrinol
(Oxf). 1995;43:575-82.
53
Kelestimur F, Sahin Y. Comparison of
Diane 35 and Diane 35 plus spironolactone
in the treatment of hirsutism. Fertil
Steril. 1998;69:66-9.
54
Kelestimur F. Diane 35 and spironolactone
combination in the treatment of
hirsutism. Clin Endocrinol (Oxf). 2001
May;54:699-700.
55
Tartagni M, Schonauer LM, De Salvia
MA, Cicinelli E, De Pergola G, D’Addario
V. Comparison of Diane 35 and Diane 35
plus finasteride in the treatment of hirsutism.
Fertil Steril. 2000;73(4):718-23.
56
Sahin Y, Dilber S, Kelestimur F. Comparison
of Diane 35 and Diane 35 plus
finasteride in the treatment of hirsutism.
Fertil Steril. 2001;75:496-500.
57
Taner C, Inal M, Basogul A. Comparison
of the clinical efficacy and safety
of flutasmide versus flutamide plus an
oral contraceptive in the treatment of
hirsutism. Gynecologic and Obstetrics
Investigation. 2002;54:105-8.
58
Unluhizarci KK, Everest H, Bayram F,
Kelestimur F. Comparison of spironolactone
and spironolactone plus finasteride
in the treatment of hirsutism. Fertil
Steril. 2002;78:1331-3.
59
Azziz R, Ehrmann D, Legro RS, Whitcomb
RW, Hanley R, Fereshetian AG,
et al. PCOS/Troglitazone Study Group
Troglitazone improves ovulation and
hirsutism in the polycystic ovary syndrome:
a multicenter, double blind, placebo-controlled
trial. J Clin Endocrinol
Metab. 2001;186:1626-32.
60
Kelly CJ, Gordon D. The effect of
metformin on hirsutism in polycystic
ovary syndrome. Eur J Endocrinol. 2002;
147(2):217-21.
61
Carr BR, Breslau NA, Givens C, Byrd
W, Barnett-Hamm C, Marshburn PB.
Oral contraceptive pills, gonadotropinreleasing
hormone agonists, or use in
combination for treatment of hirsutism:
a clinical research center study. J Clin
Endocrinol Metab. 1995;80:1169-78.
62
Azziz R, Ochoa TM, Bradley EL Jr, Potter
HD, Boots LR. Leuprolide and estrogen
versus oral contraceptive pills for the
treatment of hirsutism: a prospective
randomized study. J Clin Endocrinol
Metab. 1995;80(12):3406-11.
63
Heiner JS, Greendale GA, Kawakami
AK, Lapolt PS, Fisher M, Young D, et al.
Comparison of a gonadotropin-releasing
hormone agonist and a low dose oral
contraceptive given alone or together
in the treatment of hirsutism. J Clin
Endocrinol Metab. 1995;80:3412-8.
64
Carmina E, Janni A, Lobo RA. Physiological
estrogen replacement may enhance
the effectiveness of the gonadotropinreleasing
hormone agonist in the treatment
of hirsutism. J Clin Endocrinol
Metab. 1994;78:126-30.
65
Liew SH. Unwanted body hair and its
removal: a review. Dermatol Surg. 1999;
25:431-9.
66
Wagner RF. Physical methods for the
management of hirsutism. Cutis. 1990;
45:199-202.
67
Barman Balfour JA, McCellan K. Topical
eflornithine. Am J Clin Dermatol. 2001;
2:197-201.
68
Coyne PE Jr. The eflornithine story. J
Am Acad Dermatol. 2001;45:784-6.
69
Richards RN, Meharg GA. Electrolysis:
observations from 13 years and 140,000